Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The roles of mutant p53 in reprogramming and inflammation in breast cancers

22 Jul 2025

Abstract excerpt

Rezatapopt is an investigational small molecule p53 reactivator that binds specifically to the Y220C-mutant p53 protein without interacting with wild-type or other mutant p53 proteins. Upon binding, rezatapopt stabilizes the Y220C-mutant p53 protein in the wild-type conformation, reactivating p53 functions. The Phase 1 PYNNACLE trial assessed rezatapopt in solid tumors. One study participant with triple-negative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40696138
DOI: 10.1038/s41418-025-01549-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The roles of mutant p53 in reprogramming and inflammation in breast cancersPMID 40696138Read ↗

Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in DevelopmentSemantic proximity Read ↗

The rebel angel: mutant p53 as the driving oncogene in breast cancer.Semantic proximity Read ↗

Targeting mutant p53: a key player in breast cancer pathogenesis and beyond.Semantic proximity Read ↗

Triple-negative breast tumors are dependent on mutant p53 for growth and survival.Semantic proximity Read ↗

Role of p53 in breast cancer progression: An insight into p53 targeted therapy.Semantic proximity Read ↗

Anticancer therapeutic strategies for targeting mutant p53-Y220CSemantic proximity Read ↗

Side-Stepping the Guardian of the Genome: Current Cancer Therapeutics Targeting Mutant p53Semantic proximity Read ↗

P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.Semantic proximity Read ↗

Dysregulation of P53 in breast cancer: Causative factors and treatment strategies.Semantic proximity Read ↗

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast CancerSemantic proximity Read ↗

GOF Mutant p53 in Cancers: A Therapeutic ChallengeSemantic proximity Read ↗

Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.